Display options
Cite
Volchenboum SL, Andrade J, Huang L, et al. Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology Group. J Pathol Clin Res. 2015;1(2):83-94doi: 10.1002/cjp2.9.
Volchenboum, S. L., Andrade, J., Huang, L., Barkauskas, D. A., Krailo, M., Womer, R. B., Ranft, A., Potratz, J., Dirksen, U., Triche, T. J., & Lawlor, E. R. (2015). Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology Group. The journal of pathology. Clinical research, 1(2), 83-94. https://doi.org/10.1002/cjp2.9
Volchenboum, Samuel L, et al. "Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology Group." The journal of pathology. Clinical research vol. 1,2 (2015): 83-94. doi: https://doi.org/10.1002/cjp2.9
Volchenboum SL, Andrade J, Huang L, Barkauskas DA, Krailo M, Womer RB, Ranft A, Potratz J, Dirksen U, Triche TJ, Lawlor ER. Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology Group. J Pathol Clin Res. 2015 Apr;1(2):83-94. doi: 10.1002/cjp2.9. PMID: 26052443; PMCID: PMC4457396.
Copy Download .nbib Format: NLM
Share it on

J Pathol Clin Res. 2015 Apr;1(2):83-94. doi: 10.1002/cjp2.9.

Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology Group.

The journal of pathology. Clinical research

Samuel L Volchenboum, Jorge Andrade, Lei Huang, Donald A Barkauskas, Mark Krailo, Richard B Womer, Andreas Ranft, Jenny Potratz, Uta Dirksen, Timothy J Triche, Elizabeth R Lawlor

Affiliations

  1. Center for Research Informatics, University of Chicago ; Department of Pediatrics, University of Chicago.
  2. Center for Research Informatics, University of Chicago.
  3. Department of Preventive Medicine, Keck School of Medicine of the University of Southern.
  4. Children's Hospital of Philadelphia and University of Pennsylvania.
  5. University Hospital Muenster, Department of Pediatrics and Pediatric Hematology and Oncology.
  6. Department of Pathology, Keck School of Medicine of the University of Southern California.
  7. Department of Pediatrics and Department of Pathology, University of Michigan.

PMID: 26052443 PMCID: PMC4457396 DOI: 10.1002/cjp2.9

Abstract

Relapse of Ewing sarcoma (ES) can occur months or years after initial remission and salvage therapy for relapsed disease is usually ineffective. Thus, there is great need to develop biomarkers that can predict which patients are at risk for relapse so that therapy and post-therapy evaluation can be adjusted accordingly. For the current study we performed whole genome expression profiling on two independent cohorts of clinically annotated ES tumors in an effort to identify and validate prognostic gene signatures. ES specimens were obtained from the Children's Oncology Group (COG) and whole genome expression profiling performed using Affymetrix Human Exon 1.0 ST arrays. Lists of differentially expressed genes between survivors and non-survivors were used to identify prognostic gene signatures. An independent cohort of tumors from the Euro-Ewing cooperative group was similarly analyzed as a validation cohort. Unsupervised clustering of gene expression data failed to segregate tumors based on outcome. Supervised analysis of survivors

References

  1. PLoS One. 2013 Jun 24;8(6):e66855 - PubMed
  2. PLoS One. 2011;6(12):e28320 - PubMed
  3. J Clin Oncol. 2010 Jul 20;28(21):3506-15 - PubMed
  4. Blood. 2010 Feb 18;115(7):1394-405 - PubMed
  5. J Clin Oncol. 2012 May 10;30(14 ):1670-7 - PubMed
  6. Front Oncol. 2013 Mar 20;3:57 - PubMed
  7. Eur J Cancer. 2008 Mar;44(5):699-709 - PubMed
  8. Blood. 2009 Jul 2;114(1):144-7 - PubMed
  9. Mol Cancer Res. 2014 Jun;12(6):953-64 - PubMed
  10. Int J Biochem Cell Biol. 2014 Aug;53:493-504 - PubMed
  11. J Clin Oncol. 2010 Mar 1;28(7):1240-6 - PubMed
  12. Brief Bioinform. 2011 Nov;12(6):634-44 - PubMed
  13. BMC Bioinformatics. 2013 Apr 05;14:119 - PubMed
  14. Cancer Cell. 2010 Dec 14;18(6):553-67 - PubMed
  15. Stat Appl Genet Mol Biol. 2009;8:Article 13 - PubMed
  16. J Natl Cancer Inst. 2006 Sep 6;98 (17 ):1193-203 - PubMed
  17. J Natl Cancer Inst. 2010 Aug 18;102(16):1272-83 - PubMed
  18. BMC Cancer. 2012 Oct 18;12 :480 - PubMed
  19. Lab Invest. 2001 Jun;81(6):905-12 - PubMed
  20. Biostatistics. 2007 Jan;8(1):118-27 - PubMed
  21. Cancer. 2014 Aug 1;120(15):2334-42 - PubMed
  22. Mol Cancer. 2010 May 12;9:105 - PubMed
  23. Oncogene. 2009 Nov 19;28(46):4126-32 - PubMed
  24. J Clin Oncol. 2012 Nov 20;30(33):4148-54 - PubMed
  25. Breast Cancer Res Treat. 2013 Aug;141(1):13-22 - PubMed
  26. J Clin Oncol. 2014 Aug 10;32(23):2440-8 - PubMed
  27. Oncogene. 2004 Nov 25;23(55):8997-9006 - PubMed
  28. Cancer Res. 2013 Sep 15;73(18):5625-32 - PubMed
  29. J Clin Oncol. 2008 Sep 20;26(27):4385-93 - PubMed
  30. EMBO Mol Med. 2013 Jul;5(7):1087-102 - PubMed
  31. Nat Protoc. 2009;4(1):44-57 - PubMed
  32. Bioinformatics. 2010 Jun 15;26(12):1572-3 - PubMed
  33. J Clin Oncol. 2009 May 1;27(13):2209-16 - PubMed
  34. Front Oncol. 2013 Jun 06;3:141 - PubMed
  35. Mol Oncol. 2014 May;8(3):669-78 - PubMed
  36. J Clin Oncol. 2010 Apr 20;28(12):1989-94 - PubMed
  37. Mol Cancer Ther. 2014 Feb;13(2):483-91 - PubMed
  38. Clin Cancer Res. 2010 Jul 15;16(14):3769-78 - PubMed
  39. Lancet Oncol. 2010 Feb;11(2):184-92 - PubMed
  40. J Clin Oncol. 2013 Dec 1;31(34):4333-42 - PubMed
  41. Cancer Res. 2013 May 1;73(9):2873-83 - PubMed
  42. Clin Sarcoma Res. 2012 Dec 18;2(1):24 - PubMed
  43. Genes Chromosomes Cancer. 2014 Jul;53(7):622-33 - PubMed
  44. Clin Cancer Res. 2011 Jan 1;17 (1):56-66 - PubMed

Publication Types

Grant support